Pacira BioSciences (NASDAQ:PCRX) Stock Rating Reaffirmed by Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX – Get Rating)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $60.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 29.00% from the company’s previous close. PCRX has […]

Related Keywords

Oregon ,United States ,Arizona ,Canada ,Pacira Biosciences ,Pacira Biosciences Company Profile ,Kokusai Asset Management Co ,Pacira Biosciences Inc ,Barclays ,Advisors Asset Management Inc ,Royal Bank ,Mitsubishi Ufj ,Oregon Public Employees Retirement Fund ,Needham Company ,Get Rating ,Truist Financial ,Asset Management ,State Retirement System ,Public Employees Retirement Fund ,Pacira Biosciences Daily ,Nasdaq Pcrx ,Pcrx ,Medical ,69512710 ,Reiterated Rating ,Needham Company Llc ,